This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kawamoto, H. Articles by Uchikoshi, T. Search for Related Content PubMed PubMed Citation Articles by Kawamoto, H. Articles by Uchikoshi, T.

American Journal of Pathology, Vol 150, 15-23, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses

H Kawamoto, H Koizumi and T Uchikoshi
Second Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan.

We investigated the in vivo expression of cyclin B1 and Cdc2 (key molecules for G2-M transition during the cell cycle) in nonmalignant and cancerous human breast lesions using immunohistochemistry and quantitative proliferative index (PI) analysis. Breast epithelial cells co-expressed cyclin B1 and Cdc2 in their cytoplasm in the G2 phase and in their nuclei in the M phase. Cyclin B1, but not Cdc2, immunostaining rapidly disappeared from the nuclei during the mitotic metaphase to anaphase transition. Static image analysis revealed the mean proliferative index for cyclin B1/cdc2 for each type of lesion to be as follows: normal glands (n = 20), 2.0/2.5%; benign lesions, including typical ductal hyperplasia (n = 76), 2.5/5.8%; atypical ductal hyperplasia (n = 21), 3.0/6.6%; carcinomas in situ (n = 70), 7.4/14.0%; and invasive carcinomas (n = 58), 10.0/22.9%. Proliferative index data for atypical hyperplasia were virtually identical to those for benign lesions and were significantly lower than those for breast cancer, suggesting that expression levels of cyclin B1 and Cdc2 may be used to distinguish premalignant human breast lesions from advanced disease. Furthermore, the proliferative index for cyclin B1 for comedo-type ductal carcinomas in situ agreed with that for invasive ductal carcinomas (mean, 10.1% versus 9.5%), apparently explaining the clinicopathological aggressiveness of this tumor at the molecular level.

This article has been cited by other articles:

				Y. Song, C. Zhao, L. Dong, M. Fu, L. Xue, Z. Huang, T. Tong, Z. Zhou, A. Chen, Z. Yang, et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis Carcinogenesis, February 1, 2008; 29(2): 307 - 315. [Abstract] [Full Text] [PDF]

				L. A. Gomez, A. de las Pozas, T. Reiner, K. Burnstein, and C. Perez-Stable Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy Mol. Cancer Ther., May 1, 2007; 6(5): 1534 - 1543. [Abstract] [Full Text] [PDF]

				R. S. Roberson, S. J. Kussick, E. Vallieres, S.-Y. J. Chen, and D. Y. Wu Escape from Therapy-Induced Accelerated Cellular Senescence in p53-Null Lung Cancer Cells and in Human Lung Cancers Cancer Res., April 1, 2005; 65(7): 2795 - 2803. [Abstract] [Full Text] [PDF]

				L. W. Elmore, X. Di, C. Dumur, S. E. Holt, and D. A. Gewirtz Evasion of a Single-Step, Chemotherapy-Induced Senescence in Breast Cancer Cells: Implications for Treatment Response Clin. Cancer Res., April 1, 2005; 11(7): 2637 - 2643. [Abstract] [Full Text] [PDF]

				H. Suzuki, D. F. Graziano, J. McKolanis, and O. J. Finn T Cell-Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease Clin. Cancer Res., February 15, 2005; 11(4): 1521 - 1526. [Abstract] [Full Text] [PDF]

				H P Kourea, A K Koutras, C D Scopa, M N Marangos, E Tzoracoeleftherakis, D Koukouras, and H P Kalofonos Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma Mol. Pathol., December 1, 2003; 56(6): 328 - 335. [Abstract] [Full Text] [PDF]

				T. Nozoe, D. Korenaga, A. Kabashima, T. Ohga, H. Saeki, and K. Sugimachi Significance of Cyclin B1 Expression as an Independent Prognostic Indicator of Patients with Squamous Cell Carcinoma of the Esophagus Clin. Cancer Res., March 1, 2002; 8(3): 817 - 822. [Abstract] [Full Text] [PDF]

				H. Kao, J. A. Marto, T. K. Hoffmann, J. Shabanowitz, S. D. Finkelstein, T. L. Whiteside, D. F. Hunt, and O. J. Finn Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells J. Exp. Med., November 5, 2001; 194(9): 1313 - 1324. [Abstract] [Full Text] [PDF]

				K. A. Hassan, A. K. El-Naggar, J.-C. Soria, D. Liu, W. K. Hong, and L. Mao Clinical Significance of Cyclin B1 Protein Expression in Squamous Cell Carcinoma of the Tongue Clin. Cancer Res., August 1, 2001; 7(8): 2458 - 2462. [Abstract] [Full Text] [PDF]

				J.-C. Soria, S. J. Jang, F. R. Khuri, K. Hassan, D. Liu, W. K. Hong, and L. Mao Overexpression of Cyclin B1 in Early-Stage Non-Small Cell Lung Cancer and Its Clinical Implication Cancer Res., August 1, 2000; 60(15): 4000 - 4004. [Abstract] [Full Text]

				M. Nagata, K.-i. Nakayama, Y. Terada, S. Hoshi, and T. Watanabe Cell Cycle Regulation and Differentiation in the Human Podocyte Lineage Am. J. Pathol., November 1, 1998; 153(5): 1511 - 1520. [Abstract] [Full Text] [PDF]